Denali Q2 net loss $127.6M; AVLAYAH revenue $3.6M; PRV sale adds $195M; DNL151 discontinued in idiopathic PD

Denali Therapeutics Inc.

Q2 2026 net loss $127.6M vs $124.1M YoY; R&D $97.0M, SG&A $36.3M.
AVLAYAH (Hunter syndrome) first full quarter net revenue $3.6M; Q3 guidance $10-12M.
PRV sale closed July 2026 for $195M gross; pro forma cash >$1.1B.
DNL151 (Parkinson's) Phase 2b LUMA failed; development in idiopathic PD discontinued; BEACON study for LRRK2 carriers continues.
DNL593 (FTD-GRN) results delayed to 2027; Takeda terminated collaboration in April (strategic).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.